Skip to main content
GIPResearch.com · Patent and Technology Research

Crystal Pharma S.A.U Receives a Patent for Obtaining Alkyl Esters of Acetic Acid

Crystal Pharma SA manufactures and distributes pharmaceuticals.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for Crystal Pharma S.A.U Receives a Patent for Obtaining Alkyl Esters of Acetic Acid
Research and original publication material

Crystal Pharma S.A.U Receives a Patent for Obtaining Alkyl Esters of Acetic Acid — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Crystal Pharma SA manufactures and distributes pharmaceuticals. The Company researches, develops, and manufactures a variety of pharmaceuticals, including steroids, anti-inflammatory agents, muscle relaxers, and contraceptives. Crystal Pharma serves clients in the medical industry throughout Spain and worldwide. In India, the Pharmaceutical business of Crystal Pharma S.A.U is focused on Preparation of Indacaterol, Process for Obtaining Estetrol, Preparation of Alcaftadine, Preparation of Optically Pure Fesoterodine Derivatives. Crystal Pharma S.A.U filed patent application numbered 439/DELNP/2011 that is titled as A PROCESS FOR OBTAINING ALKYL ESTERS OF [11-(3-DIMETHYLAMINO-PROPYLIDENE)-6,11,DIHYDRO-DIBENZO[B,E]OXEPIN-2-YL-]-ACETIC ACID. This patent application has been granted as Patent Number 276054. The invention covers the field of chemical compounds. The invention states that Olopatadine can be obtained by means of a process comprising hydrolysis of a compound of general formula (II), wherein Y is OR1, wherein R1 is C1-C7 alkyl, C3-C7 cycloalkyl, aryl, arylalkyl, or heterocycle; or NR2R3, wherein R2 and R3, independently from each other, are C1-C7 alkyl, aryl, arylalkyl, or R2 and R3 together with the nitrogen atom to which they are bound form a heterocycle of 3 to 7 members, obtained by means of a process comprising reacting the corresponding ester or amide of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid with a suitable Wittig reagent, in the presence of a base in a reaction medium comprising an organic solvent. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the process is a known process. As a response, it has been claimed by Presenting Scientific difference and improved process has been shown to bring novelty. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to Crystal Pharma S.A.U Receives a Patent for

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-08-09. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights